膜修饰脂质体对缺氧心肌细胞的保护作用  

Protective effects of surface-modified liposome on the hypoxia cardiomyocytes

作　　者：邓英杰[1] 陈妍[2] 陈勇 郝艳丽[1] 张勇[1] 王汀[1] 

机构地区：[1]沈阳药科大学药学院,辽宁沈阳110016 [2]吉林大学生命科学院,吉林长春130012 [3]抚顺市第二医院药剂科,辽宁抚顺113001

出　　处：《沈阳药科大学学报》2006年第5期299-302,共4页Journal of Shenyang Pharmaceutical University

基　　金：国家自然科学基金资助项目(30271548)

摘　　要：目的考察亲脂性化合物3{4[2羟基(1甲基乙胺基)丙氧基]苯基}丙酸十六醇酯(PAC)膜修饰脂质体对缺氧心肌细胞的保护作用。方法将普通脂质体(Plain L)、PAC膜修饰脂质体(PAC L)分别于常氧和缺氧条件下与乳鼠心肌细胞共同培养1、22、4 h,荧光法测定正常与缺氧心肌细胞对脂质体的摄取,以不加脂质体的细胞为对照,台盼兰染色法测定心肌细胞存活率。结果在常氧状态下1、2、24 h心肌细胞对PAC L的摄取较Plain L分别高约3.97、3.87、4.27倍,而在缺氧状态下心肌细胞对PAC-L的摄取较Plain L分别高约4.26、6.24、29.51倍。当细胞连续缺氧24 h时,对照组、Plain L组、PAC L组的心肌细胞存活率分别为7.8%、29.7%、95.4%。结论与Plain L相比,PAC L对缺氧状态的心肌细胞具有较强的亲和性,脂质体的加入能够明显降低缺氧对心肌细胞的损伤,PAC L对缺氧心肌细胞具有较强的保护作用,效果明显优于Plain L,且随着缺氧时间的延长这种优势越显著。Objective To investigate the protective effects of 3-{ 4-[ 2-hydroxyl-（1-methyl ethylamino） propoxy]phenyl} propionic acid cetylester （PAC） surface-modified liposome on the hypoxia cardiomyocytes. Methods The Plain-L and PAC-L were incubated with cardiomyocytes under the normoxic or hypoxia condition for 1 h, 2 h, 24 h. The uptakes of Plain-L and PAC-L by cardiomyocytes were measured by fluorescence spectrophotometer. Compared with the control group without liposome, the cardiomyocytes viability of Plain-L group and PAC-L group were evaluated by trypan blue exclusion test. Results Cardiomyocyte uptake of PAC-L under the normoxic condition were 3.97-fold, 3.87-fold, and 4.27-fold higher than that of plain- L at 1 h, 2 h and 24 h; The uptake of PAC-L under the hypoxia condition were 4.26-fold, 6.24-fold, and 29.51-fold higher than that of plain-L. When anoxia persists 24 h, the cardiomyocyte viability of control group, Plain-L group and PAC-L group were 7.8 %, 29.7 %, 95.4 %, respectively. Conclusions The affinity of PAC-L to hypoxia cardiomyocytes is higher than that of Plain-L. The protective effect of PAC-L against cardiomyocyte damnification induced by hypoxia is better than that of Plain-L.

关 键 词：PAC膜修饰脂质体 普通脂质体 心肌细胞 缺氧 保护作用 

分 类 号：R943.42[医药卫生—药剂学] P945.1[医药卫生—药学]